In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.
about
The β-Lactams Strike Back: Ceftazidime-AvibactamCeftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infectionsEndless Resistance. Endless Antibiotics?Carbapenemase-producing Enterobacteriaceae.Characterization of Piperacillin/Tazobactam-Resistant Klebsiella oxytoca Recovered from a Nosocomial OutbreakMechanisms of antimicrobial resistance in Gram-negative bacilli.Multiyear, Multinational Survey of the Incidence and Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa.Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-AvibactamIn Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor CombinationsChanges in the Frequencies of β-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against β-Lactamase-Producing Isolates.In Vitro Activity of Ceftazidime-Avibactam against Isolates in a Phase 3 Open-Label Clinical Trial for Complicated Intra-Abdominal and Urinary Tract Infections Caused by Ceftazidime-Nonsusceptible Gram-Negative Pathogens.Ceftazidime-avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.Ceftazidime-avibactam (CTZ-AVI) as a treatment for hospitalized adult patients with complicated intra-abdominal infections.β-Lactams and β-Lactamase Inhibitors: An Overview.The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?Recent Advances in the Rational Design and Optimization of Antibacterial Agents.What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014In Vitro Activity of Aztreonam-Avibactam against Enterobacteriaceae and Pseudomonas aeruginosa Isolated by Clinical Laboratories in 40 Countries from 2012 to 2015.In vitro activity of ceftazidime/avibactam against urinary isolates from patients in a Phase 3 clinical trial programme for the treatment of complicated urinary tract infections.Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations.In vitro susceptibility of β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline.Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.Piperacillin-tazobactam as alternative to carbapenems for ICU patients.Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.Efficacy of ceftazidime-avibactam in a rat intra-abdominal abscess model against a ceftazidime- and meropenem-resistant isolate of Klebsiella pneumoniae carrying blaKPC-2.Unusual Escherichia coli PBP 3 Insertion Sequence Identified from a Collection of Carbapenem-Resistant Enterobacteriaceae Tested In Vitro with a Combination of Ceftazidime-, Ceftaroline-, or Aztreonam-Avibactam.Analysis of Potential β-Lactam Surrogates to Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae.In Vitro Activity of Ceftazidime-Avibactam Against Isolates from Patients in a Phase 3 Clinical Trial for the Treatment of Complicated Intra-Abdominal Infections.Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.β-lactam/β-lactamase inhibitor combinations: an updateActivity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015A Systematic Approach to the Selection of the Appropriate Avibactam Concentration for Use with Ceftazidime in Broth Microdilution Susceptibility Testing
P2860
Q26796425-65163510-F4C5-48B2-A9F1-057EF3B11BC2Q28069563-63F2B9FE-28F6-49AA-94AB-65881211FBC6Q28822179-59E8AED5-0CD0-443C-9ED6-17229CC5280DQ35751615-38773BCA-0661-4015-8181-306FD70E4BB7Q35833277-4D844E9C-750C-4547-8CEF-15351CD14655Q35935319-8AFC284C-9435-4C8A-82B2-718803926BA9Q36571962-D8C8AB39-33E5-4DB8-808B-D0656AF50984Q36644679-9EFEA9C0-4DAF-46C0-B806-001CED5059ABQ36888062-DD10B982-B3E2-48DE-8CFA-D535D0CD3C2FQ37055016-F9C39DD8-E803-4A1E-88F9-9C83FED0C396Q37120191-D2D8C0F9-DBA5-438A-A12D-635FFCA6449AQ38384435-B49B3BF9-DB75-4295-B2A7-E0EC47F86D90Q38595451-3C7D0D7C-9B7F-4526-8869-3F4881B91DAAQ38797485-656E05B3-C8E3-4DAC-8ED4-CE23E231B2B7Q38872374-A4517570-2602-41AC-91FF-18AC7B417BF7Q38892589-8B2841C6-7F98-4DF8-A8C8-62447C632291Q38958278-004FEBA8-D116-4F6B-99C0-F219D3EB47C0Q39120027-8FE93789-1D27-45A6-AABC-807B6BD2C758Q39515520-E737B25C-0A2E-466A-B622-CEF17375E819Q40166206-557DCC69-FAB5-4956-B0D3-47EA5A86C9FDQ40371584-79DA1421-4261-40E3-AEBA-31AE5C883531Q40617746-D47399FD-5CC4-4099-8069-6506D2781613Q40633420-E43260E0-8B7B-4408-A8BE-8FF243512086Q40945550-16705E7F-144F-4885-B4A1-47D973AAFD80Q41240109-4774AD23-3FC1-4D35-A746-906E2474C51AQ45711115-8958ACEA-59B0-4E3A-A84B-C6544AA08664Q46267269-487FAEE1-D597-46D4-A705-135CD302C666Q48208212-668C269A-9D81-4FF5-BEF4-8E6C0D191140Q48355486-258CBD40-D9C0-4529-86F1-E7A630A7EC03Q50048535-74BCD708-B4B5-4A07-BB94-DB650C9F406EQ52568634-1F02CA8C-374F-49FA-BCF0-36D6FAC21057Q52695014-5F6DB7A8-4873-412A-BF59-AF81859C4AC0Q57133147-0A2D237E-D207-4303-8CE6-E5C64724E0B2Q57211457-B4A83352-A2DF-4B83-A185-B419A8DB736CQ58088798-A2F449B9-D97B-473A-ACD3-0902CC844A4E
P2860
In vitro susceptibility of characterized β-lactamase-producing strains tested with avibactam combinations.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
In vitro susceptibility of cha ...... d with avibactam combinations.
@en
In vitro susceptibility of cha ...... d with avibactam combinations.
@nl
type
label
In vitro susceptibility of cha ...... d with avibactam combinations.
@en
In vitro susceptibility of cha ...... d with avibactam combinations.
@nl
prefLabel
In vitro susceptibility of cha ...... d with avibactam combinations.
@en
In vitro susceptibility of cha ...... d with avibactam combinations.
@nl
P2093
P2860
P356
P1476
In vitro susceptibility of cha ...... ed with avibactam combinations
@en
P2093
George A Jacoby
Mark Estabrook
Raymond T Testa
Wright W Nichols
P2860
P304
P356
10.1128/AAC.04191-14
P407
P50
P577
2014-12-22T00:00:00Z